Frontiers in Oncology,
Год журнала:
2023,
Номер
13
Опубликована: Окт. 24, 2023
Lung
cancer
is
a
malignancy
with
high
incidence
and
mortality
rates
globally,
it
has
5-year
survival
rate
of
only
10%–20%.
The
significant
heterogeneity
in
clinical
presentation,
histological
features,
multi-omics
findings,
drug
sensitivity
among
different
lung
patients
necessitate
the
development
personalized
treatment
strategies.
current
precision
medicine
for
cancer,
primarily
based
on
pathological
genomic
testing,
fails
to
meet
needs
clinically
refractory
cancer.
organoids
(LCOs)
are
derived
from
tumor
cells
within
tissues
generated
through
three-dimensional
tissue
culture,
enabling
them
faithfully
recapitulate
vivo
characteristics
heterogeneity.
establishment
series
LCOs
biobanks
offers
promising
platforms
efficient
screening
identification
novel
targets
anti-tumor
discovery.
Moreover,
provide
supplementary
decision-making
factors
enhance
thereby
addressing
limitations
associated
pathology-guided
approaches
managing
This
article
presents
comprehensive
review
construction
methods
potential
applications
both
preclinical
research.
It
highlights
significance
biomarker
exploration,
resistance
investigation,
target
identification,
screening,
as
well
microfluidic
technology-based
high-throughput
Additionally,
discusses
future
prospects
this
field.
Pharmacology & Therapeutics,
Год журнала:
2024,
Номер
257, С. 108631 - 108631
Опубликована: Март 11, 2024
Mouse
models
of
disease
play
a
pivotal
role
at
all
stages
cancer
drug
development.
Cell-line
derived
subcutaneous
tumour
are
predominant
in
early
discovery,
but
there
is
growing
recognition
the
importance
more
complex
orthotopic
and
metastatic
for
understanding
both
target
biology
correct
tissue
context,
impact
microenvironment
immune
system
responses
to
treatment.
The
aim
this
review
highlight
value
that
bring
study
development
while
pointing
out
those
most
likely
be
encountered
literature.
Important
developments
models,
such
as
increasing
use
passage
patient
material
(PDXs,
organoids)
humanised
mouse
discussed,
these
approaches
have
potential
increase
predictive
preclinical
studies,
ultimately
improve
success
rate
anticancer
drugs
clinical
trials.
Cancer Cell,
Год журнала:
2023,
Номер
41(12), С. 2083 - 2099.e9
Опубликована: Дек. 1, 2023
Neuroendocrine
neoplasms
(NENs)
comprise
well-differentiated
neuroendocrine
tumors
(NETs)
and
poorly
differentiated
carcinomas
(NECs).
Treatment
options
for
patients
with
NENs
are
limited,
in
part
due
to
lack
of
accurate
models.
We
establish
patient-derived
tumor
organoids
(PDTOs)
from
pulmonary
NETs
derive
PDTOs
an
understudied
subtype
NEC,
large
cell
carcinoma
(LCNEC),
arising
multiple
body
sites.
maintain
the
gene
expression
patterns,
intra-tumoral
heterogeneity,
evolutionary
processes
parental
tumors.
Through
hypothesis-driven
drug
sensitivity
analyses,
we
identify
ASCL1
as
a
potential
biomarker
response
LCNEC
treatment
BCL-2
inhibitors.
Additionally,
discover
dependency
on
EGF
NET
PDTOs.
Consistent
these
findings,
find
that,
independent
cohort,
approximately
50%
express
EGFR.
This
study
identifies
actionable
vulnerability
subset
NETs,
emphasizing
utility
PDTO
Abstract
Despite
advancements
in
treatment
protocols,
cancer
is
one
of
the
leading
cause
deaths
worldwide.
Therefore,
there
a
need
to
identify
newer
and
personalized
therapeutic
targets
along
with
screening
technologies
combat
cancer.
With
advent
pan-omics
technologies,
such
as
genomics,
transcriptomics,
proteomics,
metabolomics,
lipidomics,
scientific
community
has
witnessed
an
improved
molecular
metabolomic
understanding
various
diseases,
including
In
addition,
three-dimensional
(3-D)
disease
models
have
been
efficiently
utilized
for
pathophysiology
tools
drug
discovery.
An
integrated
approach
utilizing
3-D
vitro
tumor
led
intricate
network
encompassing
signalling
pathways
cross-talk
solid
tumors.
present
review,
we
underscore
current
trends
omics
highlight
their
role
genotypic-phenotypic
co-relation
respect
models.
We
further
discuss
challenges
associated
provide
our
outlook
on
future
applications
these
discovery
precision
medicine
management
Graphical
Abstract
The
integration
of
liquid
biopsy
with
epigenetic
markers
offers
significant
potential
for
early
lung
cancer
detection
and
personalized
treatment.
Epigenetic
alterations,
including
DNA
methylation,
histone
modifications,
noncoding
RNA
changes,
often
precede
genetic
mutations
are
critical
in
progression.
In
this
study,
we
explore
how
biopsy,
combined
markers,
can
provide
cancer,
potentially
predicting
onset
up
to
4
years
before
clinical
diagnosis.
We
discuss
the
challenges
targeting
regulators,
which
could
disrupt
cellular
balance
if
overexploited,
need
maintaining
key
gene
expressions
therapeutic
applications.
This
review
highlights
promise
using
early‐stage
diagnosis,
a
focus
on
optimizing
treatment
strategies
precision
medicine.
Frontiers in Immunology,
Год журнала:
2024,
Номер
15
Опубликована: Март 20, 2024
Organoids
present
substantial
potential
for
pushing
forward
preclinical
research
and
personalized
medicine
by
accurately
recapitulating
tissue
tumor
heterogeneity
in
vitro
.
However,
the
lack
of
standardized
protocols
cancer
organoid
culture
has
hindered
reproducibility.
This
paper
comprehensively
reviews
current
challenges
associated
with
highlights
recent
multidisciplinary
advancements
field
a
specific
focus
on
standardizing
liver
culture.
We
discuss
non-standardized
aspects,
including
sources,
processing
techniques,
medium
formulations,
matrix
materials,
that
contribute
to
technical
variability.
Furthermore,
we
emphasize
need
establish
reproducible
platforms
preserve
genetic,
proteomic,
morphological,
pharmacotypic
features
parent
tumor.
At
end
each
section,
our
shifts
standardization
primary
cancer.
By
addressing
these
challenges,
can
enhance
reproducibility
clinical
translation
systems,
enabling
their
applications
precision
medicine,
drug
screening,
research.
Journal of Translational Medicine,
Год журнала:
2024,
Номер
22(1)
Опубликована: Ноя. 8, 2024
The
complexity
of
tumors
and
the
challenges
associated
with
treatment
often
stem
from
limitations
existing
models
in
accurately
replicating
authentic
tumors.
Recently,
organoid
technology
has
emerged
as
an
innovative
platform
for
tumor
research.
This
bioengineering
approach
enables
researchers
to
simulate,
vitro,
interactions
between
their
microenvironment,
thereby
enhancing
intricate
interplay
cells
surroundings.
Organoids
also
integrate
multidimensional
data,
providing
a
novel
paradigm
understanding
development
progression
while
facilitating
precision
therapy.
Furthermore,
advancements
imaging
genetic
editing
techniques
have
significantly
augmented
potential
organoids
review
explores
application
more
precise
simulations
its
specific
contributions
cancer
research
advancements.
Additionally,
we
discuss
evolving
trends
developing
comprehensive
utilizing
technology.
Cancer Letters,
Год журнала:
2024,
Номер
588, С. 216737 - 216737
Опубликована: Фев. 19, 2024
Although
organoids
derived
from
tumor
tissues
have
been
widely
used
in
cancer
research,
it
is
a
great
challenge
for
cultured
to
retain
the
characteristics
of
original
due
their
heterogeneity.
In
this
study,
we
explore
organoid
culture
recipes
capture
features
colorectal
cancers.
We
find
that
activation
Wnt
and
EGF
signaling
inhibition
BMP
are
non-essential
survival
most
(CRCOs).
design
growth
factor-reduced
medium
containing
FGF10,
A83-01
(TGF-β
type
I
receptor
inhibitor),
SB202190
(p38
MAPK
gastrin,
nicotinamide.
Using
medium,
can
maintain
long-term
CRCO
cultivation,
as
evidenced
by
histopathology,
genetic
stability,
tumorigenicity,
response
clinical
treatments.
Our
findings
offer
reliable
economical
strategy
culture,
facilitating
utilization
research
treatment.
